

LISTING OF THE PENDING CLAIMS:

29. (Previously presented) The hybridoma cell line deposited as ATCC accession number HB-12541.

30. (Previously presented) The hybridoma cell line deposited as ATCC accession number HB-12542.

31. (Previously presented) The hybridoma cell line deposited as ATCC accession number HB-12543.

32. (Previously presented) The 4G3.9.9 monoclonal antibody produced by the hybridoma cell line deposited as ATCC accession number HB-12541.

33. (Previously presented) The 6D10.9.7 monoclonal antibody produced by the hybridoma cell line deposited as ATCC accession number HB-12542.

34. (Previously presented) The 1C5.24.1 monoclonal antibody produced by the hybridoma cell line deposited as ATCC accession number HB-12543.

55. (Previously presented) An isolated antibody which binds to an Apo-2 DcR polypeptide comprising amino acid residues 1 to 259 of Figure 1A (SEQ ID NO:1).

56. (Previously presented) An isolated antibody which binds to an extracellular domain of an Apo-2 DcR polypeptide consisting of amino acid residues 1 to X, wherein X is any one of amino acid residues 161 to 236 of Figure 1A (SEQ ID NO:1).

57. (Previously presented) The antibody of claim 55 which is a monoclonal antibody.

58. (Previously presented) The antibody of claim 56 which is a monoclonal antibody.

59. (Previously presented) The antibody of claim 57 which is a chimeric, humanized or human antibody.

60. (Previously presented) The antibody of claim 58 which is a chimeric, humanized or human antibody.

61. (Previously presented) The antibody of claim 57 which is a blocking antibody.

62. (Previously presented) The antibody of claim 58 which is a blocking antibody.

63. (Previously presented) The antibody of claim 55 or 56 which, in addition to binding said Apo-2 DcR polypeptide, binds to another Apo-2 ligand receptor selected from the group consisting of DR4, Apo-2, DcR2, and OPG.

64. (Previously presented) The antibody of claim 55 or 56 which binds to the same epitope to which the 4G3.9.9 monoclonal antibody produced by the hybridoma cell line deposited as ATCC accession number HB-12541 binds.

65. (Previously presented) The antibody of claim 55 or 56 which binds to the same epitope to which the 6D10.9.7 monoclonal antibody produced by the hybridoma cell line deposited as ATCC accession number HB-12542 binds.

66. (Previously presented) The antibody of claim 55 or 56 which binds to the same epitope to which the 1C5.24.1 monoclonal antibody produced by the hybridoma cell line deposited as ATCC accession number HB-12543 binds.

67. (Previously presented) The antibody of claim 61 which blocks binding of Apo-2 ligand to said Apo-2 DcR polypeptide.

68. (Previously presented) The antibody of claim 62 which blocks binding

of Apo-2 ligand to said Apo-2 DcR polypeptide. --